Targeting CCN Proteins in Rheumatoid Arthritis and Osteoarthritis

Iona J MacDonald1, Chien-Chung Huang2,3, Shan-Chi Liu4

  • 1Graduate Institute of Basic Medical Science, Collage of Medicine, China Medical University, Taichung 40402, Taiwan.

Insights

The CCN proteins are crucial in inflammation, angiogenesis, and wound healing. This review explores their role in rheumatoid arthritis and osteoarthritis, highlighting their therapeutic potential.

Area of Science:

  • Biochemistry and Molecular Biology
  • Immunology
  • Rheumatology

Background:

  • The CCN family of matricellular proteins (CYR61/CCN1, CTGF/CCN2, NOV/CCN3, WISP1-2-3/CCN4-5-6) are key regulators of cellular processes like proliferation, adhesion, migration, differentiation, and extracellular matrix remodeling.
  • These proteins play significant roles in angiogenesis, wound healing, and inflammation.

Purpose of the Study:

  • To review the evidence implicating CCN proteins in the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA).
  • To explore the therapeutic potential of CCN proteins as targets for treating RA and OA.

Main Methods:

  • Literature review of existing studies on CCN proteins and their involvement in inflammatory joint diseases.
  • Analysis of evidence linking specific CCN proteins (CCN1-6) to the development and progression of RA and OA.

Main Results:

  • Strong evidence implicates CCN1, CCN2, CCN3, and CCN4 in the inflammatory pathologies of RA and OA.
  • Emerging evidence suggests a role for CCN5 and CCN6 in the development of these arthritic conditions.

Conclusions:

  • The CCN protein family is significantly involved in the pathophysiology of RA and OA.
  • CCN proteins represent promising therapeutic targets for the management of inflammatory joint diseases.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.9K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277